MAIA Biotechnology, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by MAIA Biotechnology, Inc. (MAIA) on May 23, 2025, covering events occurring on May 22, 2025. The Company is incorporated in Delaware and its common stock trades on the NYSE American under the symbol "MAIA". MAIA is classified as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance actions rather than financial performance results.
Material Changes
On May 22, 2025, stockholders approved an amendment to the Company's Amended and Restated Certificate of Incorporation. The primary material change is the increase in authorized common stock from 70,000,000 shares to 150,000,000 shares. The Company subsequently filed the Certificate of Amendment with the Delaware Secretary of State on the same date.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items related to operations. The document serves solely to disclose the capital structure amendment.
Investor Verification Checklist
- Verify the effective date of the Certificate of Amendment filed with the Delaware Secretary of State.
- Review the full text of the Amendment (Exhibit 3.1) for any additional provisions beyond the share count increase.
- Confirm the current number of issued and outstanding shares to assess the remaining authorized capacity.
- Check subsequent filings for any immediate capital raises utilizing the newly authorized shares.